AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Kathmere Capital Management LLC

Kathmere Capital Management LLC lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 35.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,501 shares of the company’s stock after purchasing an additional 1,436 shares during the quarter. Kathmere Capital Management LLC’s holdings in AstraZeneca were worth $429,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Bruce G. Allen Investments LLC boosted its holdings in AstraZeneca by 19.1% in the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after acquiring an additional 138 shares during the last quarter. Carnegie Investment Counsel lifted its stake in shares of AstraZeneca by 0.8% during the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock worth $1,347,000 after purchasing an additional 138 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares in the last quarter. Sunpointe LLC lifted its stake in shares of AstraZeneca by 4.5% during the second quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock worth $267,000 after purchasing an additional 147 shares in the last quarter. Finally, Argonautica Private Wealth Management Inc. increased its position in shares of AstraZeneca by 4.0% during the second quarter. Argonautica Private Wealth Management Inc. now owns 3,874 shares of the company’s stock worth $302,000 after acquiring an additional 149 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN stock opened at $77.62 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The business has a 50 day moving average of $81.68 and a two-hundred day moving average of $77.03. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a market cap of $240.66 billion, a P/E ratio of 38.05, a PEG ratio of 1.45 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.01. The business had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.08 earnings per share. As a group, analysts anticipate that AstraZeneca PLC will post 4.05 EPS for the current year.

AstraZeneca Cuts Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were given a dividend of $0.49 per share. The ex-dividend date was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio is presently 48.04%.

Analyst Ratings Changes

A number of analysts have recently issued reports on AZN shares. TD Cowen lifted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Citigroup raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Finally, Barclays raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.